cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Prothena Corporation Plc
4 own
7 watching
Current Price
$30.32
$2.14
(7.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,898.47M
52-Week High
52-Week High
79.65000
52-Week Low
52-Week Low
24.28500
Average Volume
Average Volume
0.77M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
43.4636
iconMarket Capitalization1,898.47M
icon52-Week High79.65000
icon52-Week Low24.28500
iconAverage Volume0.77M
iconDividend Yield--
iconP/E Ratio43.4636
What does the Prothena Corporation Plc do?
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson's disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dun Laoghaire, Ireland.
Read More
How much money does Prothena Corporation Plc make?
News & Events about Prothena Corporation Plc.
Ticker Report
8 months ago
Prothena Co. plc (NASDAQ:PRTA Get Rating) insider Hideki Garren sold 4,669 shares of the firms stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $74.22, for a total value of $346,533.18. The transaction was disclosed in a legal filing with ...
Business Wire
11 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (A) product...
Ticker Report
12 months ago
Prothena Co. plc (NASDAQ:PRTA Get Rating) Stock analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Prothena in a research note issued to investors on Friday, February 24th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company ...
Business Wire
1 year ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the...
Business Wire
1 year ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today presented data from the completed phase 3 VITAL study demonstrating that in a post hoc analysis of patients with...
Frequently Asked Questions
Frequently Asked Questions
What is Prothena Corporation Plc share price today?
plus_minus_icon
Can Indians buy Prothena Corporation Plc shares?
plus_minus_icon
How can I buy Prothena Corporation Plc shares from India?
plus_minus_icon
Can Fractional shares of Prothena Corporation Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Prothena Corporation Plc stocks?
plus_minus_icon
What is today’s traded volume of Prothena Corporation Plc?
plus_minus_icon
What is today’s market capitalisation of Prothena Corporation Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Prothena Corporation Plc?
plus_minus_icon
What percentage is Prothena Corporation Plc down from its 52-Week High?
plus_minus_icon
What percentage is Prothena Corporation Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$30.32
$2.14
(7.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00